Article
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2002
Kaufmann Andreas M, Stern Peter L, Rankin Elaine M, Sommer Harald, Nuessler Volkmar, Schneider Achim, Adams Malcom, Onon Toli S, Bauknecht Thomas, Wagner Uwe, Kroon Karlijn, Hickling Julian, Boswell Christopher M, Stacey Simon N, Kitchener Henry C, Gillard Jennifer, Wanders Jantien, Roberts John St C, Zwierzina Heinz
Abstract excerpt
PURPOSE: Cervical cancer, the second most common malignancy in women worldwide, is almost invariably associated with infection by human papillomavirus (HPV). HPV-16 or -18 is commonly present in 70% of cervical cancers. HPV-positive tumor cells present antigens of the viral protein in the context of human leukocyte antigen (HLA) class I that can be recognized by CTLs. We have conducted a study in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.